Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
Meta-analysis: The efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer
Journal of Digestive Diseases, 10/29/09
Ran ZH et al. – The authors results confirmed that monoclonal antibody targeted to EGFR could be effective in increasing response rates and could be a key therapeutic agent in the optimal treatment of mCRC, despite a moderate increase in grades 3–4 adverse events.
Related Articles
Visceral Fat Volume and the Prevalence of Colorectal Adenoma
American Journal of Epidemiology, 11/19/09
Relevance Score: 68%
P73 expression and its clinical significance in colorectal cancer
Colorectal Disease, 10/19/09
Relevance Score: 68%
Surgical management of colorectal liver metastases
Community Oncology, 10/09/09
Relevance Score: 68%
The effect of aspirin in the recurrence of colorectal adenomas: a meta-analysis of randomized controlled trials
Colorectal Disease, 10/15/09
Relevance Score: 67%
Aspirin as Colorectal Cancer Adjuvant Therapy
Gastroenterology, 10/05/09
Relevance Score: 67%
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Distinct features of colorectal cancer in children and adolescents
Cancer, 12/15/09
Position Statement: Nonanesthesiologist Administration of Propofol for GI Endoscopy
Gastroenterology, 12/15/09
Colorectal cancer: incidence and trend in Brunei Darussalam
Singapore Medical Journal, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


